NEXALIN TECHNOLOGY INC

“Nexalin’s stock dives 5% as investors question its unverified bio‑electronic therapy claims, thin cash flow, and lack of regulatory approval – a cautionary tale for biotech speculators.”

Explore how Nexalin (NXL) navigates market volatility and eyes growth through FDA milestones, mass‑production scaling, and direct‑to‑consumer bioelectronic devices targeting anxiety and insomnia.